171 related articles for article (PubMed ID: 28007545)
21. Low powder mass filling of dry powder inhalation formulations.
Eskandar F; Lejeune M; Edge S
Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs.
Garcia-Contreras L; Padilla-Carlin DJ; Sung J; VerBerkmoes J; Muttil P; Elbert K; Peloquin C; Edwards D; Hickey A
J Pharm Sci; 2017 Jan; 106(1):331-337. PubMed ID: 27842973
[TBL] [Abstract][Full Text] [Related]
23. New dry powders for inhalation containing temozolomide-based nanomicelles for improved lung cancer therapy.
Rosière R; Gelbcke M; Mathieu V; Van Antwerpen P; Amighi K; Wauthoz N
Int J Oncol; 2015 Sep; 47(3):1131-42. PubMed ID: 26201404
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
25. Pulmonary Delivery of Vancomycin Dry Powder Aerosol to Intubated Rabbits.
Sullivan BP; El-Gendy N; Kuehl C; Berkland C
Mol Pharm; 2015 Aug; 12(8):2665-74. PubMed ID: 25915095
[TBL] [Abstract][Full Text] [Related]
26. Performance tuning of particle engineered mannitol in dry powder inhalation formulations.
Hertel N; Birk G; Scherließ R
Int J Pharm; 2020 Aug; 586():119592. PubMed ID: 32622814
[TBL] [Abstract][Full Text] [Related]
27. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection.
Arora S; Haghi M; Loo CY; Traini D; Young PM; Jain S
Mol Pharm; 2015 Jun; 12(6):2001-9. PubMed ID: 25923171
[TBL] [Abstract][Full Text] [Related]
28. Targeted PEG-poly(glutamic acid) complexes for inhalation protein delivery to the lung.
Nieto-Orellana A; Li H; Rosiere R; Wauthoz N; Williams H; Monteiro CJ; Bosquillon C; Childerhouse N; Keegan G; Coghlan D; Mantovani G; Stolnik S
J Control Release; 2019 Dec; 316():250-262. PubMed ID: 31678655
[TBL] [Abstract][Full Text] [Related]
29. Development of Sustained Release Oseltamivir Phosphate Dry Powder Inhaler:
Sahastrabudhe H; Kenjale P; Pokharkar V
Curr Drug Deliv; 2020; 17(8):703-710. PubMed ID: 32472998
[TBL] [Abstract][Full Text] [Related]
30. Dry powder aerosol delivery systems: current and future research directions.
Chan HK
J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
[TBL] [Abstract][Full Text] [Related]
31. Dexamethasone palmitate large porous particles: A controlled release formulation for lung delivery of corticosteroids.
N'Guessan A; Fattal E; Chapron D; Gueutin C; Koffi A; Tsapis N
Eur J Pharm Sci; 2018 Feb; 113():185-192. PubMed ID: 28890202
[TBL] [Abstract][Full Text] [Related]
32. Preparation and evaluation of poly(lactic-co-glycolic acid) microparticles as a carrier for pulmonary delivery of recombinant human interleukin-2: II. In vitro studies on aerodynamic properties of dry powder inhaler formulations.
Devrim B; Bozkır A; Canefe K
Drug Dev Ind Pharm; 2011 Nov; 37(11):1376-86. PubMed ID: 21548727
[TBL] [Abstract][Full Text] [Related]
33. Controlled release antibiotics for dry powder lung delivery.
Adi H; Young PM; Chan HK; Salama R; Traini D
Drug Dev Ind Pharm; 2010 Jan; 36(1):119-26. PubMed ID: 19656005
[TBL] [Abstract][Full Text] [Related]
34. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
35. Dry powders for oral inhalation free of lactose carrier particles.
Healy AM; Amaro MI; Paluch KJ; Tajber L
Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
[TBL] [Abstract][Full Text] [Related]
36. The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder.
Yang MY; Verschuer J; Shi Y; Song Y; Katsifis A; Eberl S; Wong K; Brannan JD; Cai W; Finlay WH; Chan HK
Int J Pharm; 2016 Nov; 513(1-2):294-301. PubMed ID: 27639621
[TBL] [Abstract][Full Text] [Related]
37. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
38. Tuning aerosol performance using the multibreath Orbital® dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry.
Zhu B; Young PM; Ong HX; Crapper J; Flodin C; Qiao EL; Phillips G; Traini D
J Pharm Sci; 2015 Jul; 104(7):2169-76. PubMed ID: 25931324
[TBL] [Abstract][Full Text] [Related]
39. Methods for reduction of cohesive forces between carrier and drug in DPI formulation.
Desai SS; Aher AA; Kadaskar PT
Drug Dev Ind Pharm; 2013 Nov; 39(11):1589-98. PubMed ID: 23050727
[TBL] [Abstract][Full Text] [Related]
40. In vitro evaluation of the DP-4M PennCentury insufflator.
Hoppentocht M; Hoste C; Hagedoorn P; Frijlink HW; de Boer AH
Eur J Pharm Biopharm; 2014 Sep; 88(1):153-9. PubMed ID: 24993307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
